Core Viewpoint - A class action securities lawsuit has been filed against XPLR Infrastructure, LP, formerly known as Nextera Energy Partners, LP, alleging securities fraud that affected investors between September 27, 2023, and January 27, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that the defendants made false statements and concealed critical information regarding XPLR's operational struggles as a yieldco [3]. - It is alleged that the defendants entered into financing arrangements to temporarily alleviate operational issues while downplaying associated risks [3]. - The complaint states that XPLR could not resolve these financings before their maturity without risking significant dilution of unitholders [3]. - As a result of these issues, the defendants planned to halt cash distributions to investors to redirect funds towards resolving financing problems [3]. - The lawsuit asserts that XPLR's yieldco business model and distribution growth rate were unsustainable, rendering the defendants' public statements materially false and misleading [3]. Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until September 8, 2025, to request appointment as lead plaintiff [4]. - Participation in the lawsuit does not require serving as a lead plaintiff, and class members may be entitled to compensation without any out-of-pocket costs [4]. Group 3: Firm Background - Levi & Korsinsky, LLP has a history of securing hundreds of millions of dollars for shareholders and has been recognized as one of the top securities litigation firms in the United States for seven consecutive years [5].

Core Viewpoint - Iovance Biotherapeutics, Inc. is facing a class action securities lawsuit due to alleged securities fraud that negatively impacted investors between May 9, 2024, and May 8, 2025 [1][2]. Group 1: Allegations and Financial Impact - The lawsuit claims that Iovance provided misleadingly positive statements while concealing material adverse facts about its growth potential, specifically its inability to generate demand for its treatments [2]. - On July 25, 2024, Iovance announced a reduction in its revenue guidance for fiscal year 2024, attributing this to maintenance issues, lower-than-expected Proleukin sales, and a variable pace in treatment initiation [2]. - Following the announcement, Iovance's stock price plummeted from $3.17 per share on May 8, 2025, to $1.75 per share on May 9, 2025, marking a decline of approximately 44.8% in one day [2]. Group 2: Legal Proceedings and Participation - Investors who suffered losses during the specified period have until July 14, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require this role [3]. - Class members may be entitled to compensation without incurring any out-of-pocket costs or fees [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years [4]. - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the leading securities litigation firms in the United States [4].

Core Viewpoint - A class action securities lawsuit has been filed against Organon & Co. due to alleged securities fraud that affected investors between October 31, 2024, and April 30, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that Organon's management made overly positive statements while concealing material adverse facts about the company's capital allocation priorities, particularly regarding a significant debt reduction strategy following the acquisition of Dermavant [2]. - As a result of these actions, Organon reduced its regular quarterly dividend by 70%, leading to a dramatic decline in stock price from $12.93 per share on April 30, 2025, to $9.45 per share on May 1, 2025, representing a drop of over 27% in just one day [2]. Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until July 22, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require serving as a lead plaintiff [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [3]. Group 3: Firm Background - Levi & Korsinsky has a strong track record, having secured hundreds of millions of dollars for shareholders over the past 20 years and is recognized as one of the top securities litigation firms in the United States [4].

NEW YORK, July 14, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Red Cat Holdings, Inc. ("Red Cat Holdings, Inc." or the "Company") (NASDAQ: RCAT) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Red Cat Holdings, Inc. investors who were adversely affected by alleged securities fraud between March 18, 2022 and January 15, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com ...

Core Viewpoint - A class action securities lawsuit has been filed against Organon & Co. due to alleged securities fraud that negatively impacted investors between October 31, 2024, and April 30, 2025 [1] Group 1: Lawsuit Details - The lawsuit claims that Organon's management made overly positive statements while concealing material adverse facts about the company's capital allocation priorities, particularly regarding its debt reduction strategy after acquiring Dermavant [2] - Following the revelation of a 70% decrease in the regular quarterly dividend, Organon's stock price plummeted from $12.93 per share on April 30, 2025, to $9.45 per share on May 1, 2025, marking a decline of over 27% in just one day [2] Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until July 22, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require serving as a lead plaintiff [3] - Class members may be entitled to compensation without incurring any out-of-pocket costs or fees [3] Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the United States, with over 70 employees dedicated to serving clients [4]

Core Viewpoint - A class action securities lawsuit has been filed against 3D Systems Corporation, alleging securities fraud that negatively impacted investors between August 13, 2024, and May 12, 2025 [1][2]. Group 1: Allegations of Fraud - The lawsuit claims that 3D Systems Corporation understated the impact of weakened customer spending on its business while overstating its resilience in challenging industry conditions [2]. - It is also alleged that updated milestone criteria in the partnership with United Therapeutics Corporation would adversely affect the revenue from the Company's regenerative medicine program [2]. - As a result, the Company's public statements were deemed materially false and misleading throughout the relevant period [2]. Group 2: Legal Process and Participation - Investors who suffered losses during the specified timeframe have until August 12, 2025, to request to be appointed as lead plaintiff in the case [3]. - Participation in the lawsuit does not require serving as a lead plaintiff, and class members may be entitled to compensation without any out-of-pocket costs or fees [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a history of securing hundreds of millions of dollars for shareholders and has been recognized as one of the top securities litigation firms in the United States for seven consecutive years [4].

Core Viewpoint - A class action securities lawsuit has been filed against Red Cat Holdings, Inc. for alleged securities fraud affecting investors between March 18, 2022, and January 15, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that the defendants made false statements regarding the production capacity of the Salt Lake City Facility and the value of the U.S. Army's Short Range Reconnaissance Program of Record Tranche 2 contract, leading to materially false and misleading public statements [2]. - Investors who suffered losses during the specified timeframe have until July 22, 2025, to request to be appointed as lead plaintiff, although participation does not require serving in this role [3]. Group 2: Legal Representation - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years and consistently ranking among the top securities litigation firms in the U.S. [4].

Core Viewpoint - A lawsuit has been filed against Iovance Biotherapeutics, Inc. and certain senior executives for potential violations of federal securities laws, specifically related to the company's performance and treatment timelines for its melanoma drug Amtagvi [1][2]. Company Overview - Iovance Biotherapeutics is a commercial-stage biopharmaceutical company focused on developing treatments for melanoma and other solid tumor cancers [3]. Product Launch and Issues - Iovance launched its key melanoma treatment, Amtagvi, in February 2024, but has faced challenges with its authorized treatment centers (ATCs) [3]. - The company claimed that its ATCs would drive demand for Amtagvi; however, there were long timelines for patient treatment initiation and ineffective patient identification, leading to high patient drop-offs [4]. Financial Performance - On May 8, 2025, Iovance reported disappointing financial results for the first quarter of 2025 and revised its full-year 2025 revenue guidance downward due to "recent launch dynamics" and high patient drop-off rates [5]. - Following the announcement, Iovance's stock price fell over 44%, from $3.17 per share to $1.75 per share within a day [6].

Core Viewpoint - A lawsuit has been filed against Organon & Co. and its senior executives for potential violations of federal securities laws, particularly related to misleading statements about dividend policies following a significant acquisition [1][2][3]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the District of New Jersey, titled Hauser v. Organon & Co., et al., No. 25-cv-05322, and claims are made under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [2]. - Investors have until July 22, 2025, to request to be appointed to lead the case [2]. Group 2: Company Background and Acquisition - Organon is a global healthcare company focused on women's health and has historically provided healthy dividends to its shareholders [3]. - In October 2024, Organon completed a $1.2 billion acquisition of Dermavant, a biopharmaceutical company, which increased its debt [3]. Group 3: Dividend Policy and Stock Performance - Following the acquisition, Organon assured investors it would maintain its dividend, claiming it was the "1 capital allocation priority," but later shifted focus to debt reduction, leading to a significant dividend cut [3]. - On May 1, 2025, Organon announced a reduction in its dividend payout from $0.28 per share to $0.02 per share, resulting in a stock price decline of approximately 27%, from $12.93 to $9.45 per share [4].

Group 1 - The core issue involves a class action lawsuit against Rocket Pharmaceuticals, alleging violations of the Securities Exchange Act of 1934 related to misleading statements about the safety and clinical trial protocol of its gene therapy product RP-A501 [1][4][5] - The lawsuit claims that Rocket Pharmaceuticals failed to disclose serious adverse events, including patient deaths, during a Phase 2 clinical trial for Danon disease, which led to a significant drop in the company's stock price following the FDA's clinical hold announcement [4][5] - Investors who purchased Rocket Pharmaceuticals securities between February 27, 2025, and May 26, 2025, are eligible to seek appointment as lead plaintiff in the class action lawsuit [1][6] Group 2 - Rocket Pharmaceuticals is characterized as a late-stage biotechnology company focused on developing gene therapies for rare diseases [3] - The law firm Robbins Geller Rudman & Dowd LLP, known for its expertise in securities fraud litigation, is representing the investors in this class action case [7]